Streetbeat News

GRI

GRI Bio, Inc.

https://www.gribio.com

Industry

Biotechnology

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Open

0.73

Mkt cap

2.3M

Volume

654K

High

0.90

P/E Ratio

0.01

52-wk high

106.29

Low

0.72

Div yield

N/A

52-wk low

0.30

The article highlights four health care stocks that are considered oversold based on their Relative Strength Index (RSI) values, suggesting they may be undervalued and could potentially rise in Q1. The stocks mentioned are iBio, Inc. (IBIO), GRI Bio, Inc. (GRI), AlloVir, Inc. (ALVR), and VYNE Therapeutics Inc. (VYNE). Each company has experienced significant stock price declines, with their RSI values falling below 30, which is typically considered an oversold condition.

Portfolio Pulse from Avi Kapoor

January 16, 2024 | 11:50 am

During Friday's intraday session, several healthcare stocks experienced significant movements. Jin Medical International (ZJYL) saw a substantial rise of 85.2%, while Karuna Therapeutics (KRTX) increased by 47.07%. Conversely, AlloVir (ALVR) plummeted by 65.7%. Other notable movers included IMAC Hldgs (BACK), PureTech Health (PRTC), HeartBeam (BEAT), Neumora Therapeutics (NMRA), Cyclacel Pharmaceuticals (CYCC), 60 Degrees (SXTP), Nanobiotix (NBTX), Trinity Biotech (TRIB), and GRI Bio (GRI).

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:31 pm

Daktronics, Inc. (NASDAQ:DAKT) shares fell over 10% due to weaker-than-expected quarterly results, with earnings of 5 cents per share versus the estimated 13 cents and sales of $199.37 million against the expected $213.70 million. Other stocks experienced significant movements in Tuesday's mid-day session, with notable gainers including Meiwu Technology Company Limited (WNW), Volato Group, Inc. (SOAR), and Clearmind Medicine Inc. (CMND), among others. Losers included Replimune Group, Inc. (REPL), iBio, Inc. (IBIO), and Designer Brands Inc. (DBI), which all saw substantial declines in their share prices.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 6:06 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. PHAXIAM Therapeutics (PHXM) saw a 22.1% increase, while Travere Therapeutics (TVTX) rose by 20.66%. MSP Recovery (LIFW) and Xenetic Biosciences (XBIO) also saw gains of 18.99% and 17.84%, respectively. Cerevel Therapeutics (CERE) and Kala Bio (KALA) shares went up by 16.28% and 15.92%. On the downside, Replimune Group (REPL) dropped by 44.5%, iBio (IBIO) by 43.66%, Seelos Therapeutics (SEEL) by 25.26%, Mainz Biomed (MYNZ) by 25.16%, GRI Bio (GRI) by 23.35%, and Brainstorm Cell (BCLI) by 16.45%.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 5:31 pm

GitLab Inc. (GTLB) shares surged over 16% in pre-market trading following the release of Q3 earnings that surpassed expectations and a strong FY24 forecast. The company reported earnings of $0.09 per share against expected losses of $0.01 per share, with sales of $149.70 million beating estimates of $141.49 million. GitLab anticipates FY24 earnings of $0.12 to $0.13 per share, compared to expected losses of $0.06 per share, and revenue projections of $573 million to $574 million, above the $558.14 million estimate.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 2:04 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. NexImmune (NEXI) saw a dramatic increase of 343.1%, while Altimmune (ALT) and Biora Therapeutics (BIOR) also posted substantial gains. Conversely, Ampio Pharmaceuticals (AMPE) and LumiraDx (LMDX) led the decliners with significant drops in their stock prices.

Portfolio Pulse from Benzinga Insights

December 01, 2023 | 1:06 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Impel Pharmaceuticals (IMPL) saw a dramatic increase of 141.4%, while Entrada Therapeutics (TRDA) faced a sharp decline of 33.1%. Other notable gainers include Conduit Pharmaceuticals (CDT), Telesis Bio (TBIO), AquaBounty Techs (AQB), PaxMedica (PXMD), and Seelos Therapeutics (SEEL). On the losing side, Alterity Therapeutics (ATHE), GRI Bio (GRI), Inspire Veterinary (IVP), Altamira Therapeutics (CYTO), and Mira Pharmaceuticals (MIRA) saw their stock prices fall.

Portfolio Pulse from Benzinga Insights

November 23, 2023 | 5:31 pm

After Wednesday's after-market session, several healthcare stocks experienced significant movements. Bone Biologics (BBLG) saw a 56.0% increase after Q3 earnings, while Exagen (XGN) and PAVmed (PAVM) also rose following their earnings reports. Conversely, Augmedix (AUGX), Impel Pharmaceuticals (IMPL), and others saw their stock prices decline. The movements were accompanied by notable trading volumes for some of the stocks.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 9:31 pm

In Wednesday's after-market session, several healthcare stocks saw significant movement. Gainers included Clene (CLNN), AcelRx Pharmaceuticals (ACRX), Assembly Biosciences (ASMB), GRI Bio (GRI), China SXT Pharmaceuticals (SXTC), and Biomerica (BMRA). Losers included Align Tech (ALGN), Simulations Plus (SLP), Alpha Tau Medical (DRTS), Reshape Lifesciences (RSLS), Forian (FORA), and Panbela Therapeutics (PBLA).

Portfolio Pulse from Benzinga Insights

October 25, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.